Role of oral anticoagulants in patients after an acute coronary syndrome.

Edward T Carreras, Jessica L Mega

Journal: Arteriosclerosis, thrombosis, and vascular biology 2016;35(3):520-4

PMID: 25614282

Abstract

After an acute coronary syndrome, patients continue to be at risk of adverse cardiovascular events despite treatment with the current standard of antithrombotic therapy. The risk may be in part secondary to thrombin, which remains elevated after an acute coronary syndrome event. Several studies have investigated the utility of adding oral anticoagulation to post-acute coronary syndrome medical regimens, with the most promising results coming from the addition of low-dose oral direct anticoagulants. Focusing on optimal dosing strategies and applying therapies to the appropriate populations provide the ability to maximize benefit and minimize risk.

Address: From the TIMI Study Group (J.L.M.), Division of Cardiovascular Medicine (E.T.C., J.L.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; From the TIMI Study Group (J.L.M.), Division of Cardiovascular Medicine (E.T.C., J.L.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. [email protected].

DOI: 10.1161/ATVBAHA.114.303401

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Acute Coronary Syndrome, Administration, Oral, Anticoagulants, Drug Dosage Calculations, Drug Therapy, Combination, Fibrinolytic Agents, Humans, Platelet Aggregation Inhibitors, Risk Factors, Treatment Outcome